BioCentury | Jun 26, 2020
Distillery Therapeutics

AADAC identified as protective factor against diabetic atherosclerosis

...Israel Deaconess Medical Center (BIDMC), Harvard Medical School, Boston, Mass.; Harvard University, Cambridge, Mass. email: ccowan@fas.harvard.edu Claire...
BioCentury | Dec 20, 2019
Financial News

Forma’s $100M series D cements pivot from discovery shop to heme and cancer therapeutics

...developing FT-4101, a systemic FASN inhibitor in Phase I/II testing, and FT-8225, a preclinical liver-targeted FASN...
...and an undisclosed healthcare investment fund. Targets: CBP - CREB binding protein; FASN (FAS) - Fatty acid synthase...
BioCentury | Aug 5, 2019
Financial News

Aug. 5 Financial Quick Takes: Biotech tumbles with broader markets; plus Exo, 3-V and more

...TVB-2640 for non-alcoholic steatohepatitis (NASH). Ascletis has exclusive rights to the inhibitor of fatty acid synthase (FASN; FAS...
BioCentury | Jul 18, 2019
Distillery Techniques

David Liu uses anionic human protein for efficient cellular delivery of gene editing proteins

...David Liu, Broad Institute of Harvard and MIT, Cambridge, Mass.; Harvard University, Cambridge, Mass. e-mail: drliu@fas.harvard.edu Sandi...
BioCentury | Apr 15, 2019
Distillery Therapeutics

CPS1 protein to treat drug-induced liver toxicity

...testing recombinant CPS1 in larger animal models of liver injury. TARGET/MARKER/PATHWAY: Carbamoyl-phosphate synthase 1 (CPS1); Fas...
BioCentury | Mar 19, 2019
Distillery Therapeutics

Inhibiting FASL for ischemic stroke

...s.r.l. has PC111, a human mAb against FASL, in preclinical testing for pemphigus vulgaris. TARGET/MARKER/PATHWAY: Fas...
...2019 doi:10.1073/pnas.1814394116 CONTACT: Yun Xu, Medical School of Nanjing University, Nanjing, China email: xuyun20042001@aliyun.com Claire Quang Nanjing University Fas...
BioCentury | Feb 15, 2019
Company News

3-V raises $18M, partners NASH program with Ascletis

...Pharma Inc. (HKEX:1672) exclusive rights in Greater China to TVB-2640, an inhibitor of fatty acid synthase (FASN; FAS...
...tiered royalties up to the mid teens. 3-V has begun Phase II testing of the FASN...
...Ascletis Pharma Inc. (HKSE:1672), Hangzhou, China Business: Hepatic Hongjiang Li FAS inhibitor (TVB-2640) 3-V Biosciences Inc. Ascletis BioScience Co. Ltd. Fatty acid synthase (FASN) (FAS)...
BioCentury | Feb 13, 2019
Financial News

3-V raises $18M, partners NASH program with Ascletis

...Pharma Inc. (HKEX:1672) exclusive rights in Greater China to TVB-2640, an inhibitor of fatty acid synthase (FASN; FAS...
...tiered royalties up to the mid teens. 3-V has begun Phase II testing of the FASN...
...enter clinical development, according to BioCentury's BCIQ database. Hongjiang Li FAS inhibitor (TVB-2640) 3-V Biosciences Inc. Ascletis BioScience Co. Ltd. Fatty acid synthase (FASN) (FAS)...
BioCentury | Feb 13, 2019
Distillery Therapeutics

Cancer

...CD95 inhibitor ONL1204 in preclinical testing for age-related macular degeneration (AMD) and retinal detachment. TARGET/MARKER/PATHWAY: Fas...
...Klebanoff, Memorial Sloan Kettering Cancer Center, New York, N.Y. email: klebanoc@mskcc.org Claire Quang Memorial Sloan Kettering Cancer Center CD19 Fas...
BioCentury | Nov 30, 2018
Targets & Mechanisms

Revving up metabolism at ASH 2018

...NOS2; iNOS) 6 Fatty acid synthesis Acetyl-Coenzyme A carboxylase α (ACACA; ACC1) 3 Fatty acid synthase (FASN; FAS...
Items per page:
1 - 10 of 166